Unity Biotechnology, Inc. (UNBX)
| Market Cap | 965.60K -95.9% |
| Revenue (ttm) | n/a |
| Net Income | -27.50M |
| EPS | -1.63 |
| Shares Out | 17.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,707 |
| Open | 0.0563 |
| Previous Close | 0.0559 |
| Day's Range | 0.0555 - 0.0618 |
| 52-Week Range | 0.0487 - 3.1000 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2025 |
About Unity Biotechnology
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the... [Read more]
Financial Performance
Financial StatementsNews
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ag...
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc...
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today st...
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today an...
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agin...
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of a...
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or rev...
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more ...
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi...
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeks
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET Program Update with retinal expert and seni...
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...